BMC Cancer
- YANG S, Du J, Wang W, Zhou D, et al
APOC1 is a prognostic biomarker associated with M2 macrophages in ovarian cancer.
BMC Cancer. 2024;24:364.
Cancer
- RIMEL BJ, Enserro D, Bender DP, Jackson CG, et al
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the
combination of cediranib/olaparib in women with recurrent, persistent, or
metastatic endometrial cancer.
Cancer. 2023 Dec 21. doi: 10.1002/cncr.35151.
Gynecol Oncol
- HARTMAN YAW, Kenkhuis MF, Stelten S, Brouwer CG, et al
Demographic, clinical, and sociocognitive determinants related to physical
activity and dietary intake in patients with ovarian cancer: A cross-sectional
study.
Gynecol Oncol. 2024;183:39-46.
- MCNAMARA B, Demirkiran C, Hartwich TMP, Bellone S, et al
Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK
inhibition in low grade serous ovarian cancer.
Gynecol Oncol. 2024 Feb 9:S0090-8258(24)00043.
- BYRNE M, Sia TY, Fong C, Khurram A, et al
Mainstreaming in parallel with ovarian cancer tumor testing to improve genetic
testing uptake.
Gynecol Oncol. 2024 Mar 14:S0090-8258(24)00144.
- LEVINE BJ
Letter re: Ban et al., A personalized probabilistic approach to ovarian cancer
diagnostics.
Gynecol Oncol. 2024 Mar 15:S0090-8258(24)00155.
Int J Gynaecol Obstet
- WANG D, Ran X, He Y, Zhu L, et al
Nomograms for predicting overall survival and cancer-specific survival of
endometrioid ovarian carcinoma: A retrospective cohort study from the SEER
database.
Int J Gynaecol Obstet. 2023 Nov 27. doi: 10.1002/ijgo.15263.
Oncology (Williston Park)
- KOSTRZANOWSKI M, Ziolkowski G, Dabrowski F
Extreme Case of Surgical Port Metastasis in Ovarian Cancer.
Oncology (Williston Park). 2024;38:110-114.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016